Fundraising FoxOMX Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew MaterialsCambridge, GB
Jason Chin(Professor)Jason W. Chin(Founder)Julius Fredens(Founder)Ola Wlodek, PhD(CEO)Prof. Jason Chin, PhD(CSO & Founder)
Co-investors+ND CapitalAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCPaladin Capital Group+2 more
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsArtis VenturesBlack FlagCivilization Ventures Management, LlcFoundersX VenturesGaingelsHarpoon Ventures+10 more
__Twitter.png)
Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms.
AI & Machine LearningBiotechMedical DevicesNew York, US
Dr. Legut(Co-Founder and CEO)Dr. Sanjana(Co-Founder)Mateusz Legut(Executive Officer, Director)Neville Sanjana(Director)Mat Legut(Founder)in
BoardVasudev Bailey(Director)in
Co-investorsArtis VenturesCivilization Ventures Management, LlcFusionGaingelsHAWKTAILWing+2 more
Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, GB
Dr Jack Kennefick(Co-founder, Director & Chief Executive Officer)Dr Robert Neely(Co-founder, Director & Chief Scientific Officer)
Co-investorsCalculus Capital Ltd.Illumina VenturesIQ CapitalCalculusInnovate UKMEIF Proof-of-Concept & Early Stage Fund+2 more
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.